Key facts
- It has raised $970K across 1 recorded rounds; the latest was Seed Round ($770K) in May 2021.
- Protibea Therapeutics has filed 2 Form Ds with the SEC since 2021, most recently Aug 2025 ($200K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Protibea Therapeutics
Funding rounds
1 roundsAbout Protibea Therapeutics
Developer of immune dysregulation Alzheimer's disease therapeutics designed to address the underlying immune mechanisms associated with neurodegeneration. The company focuses on novel treatments that modulate immune system pathways implicated in neurodegeneration, to improve outcomes for patients affected by Alzheimer's disease, enabling patients with new therapeutic options for a condition with significant unmet medical need.
- Sector
- Healthcare
- HQ
- Georgetown, TX, United States
- Founded
- 2021
- Website
- protibea.com/
- Ownership
- Privately Held (backing)
Protibea Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Protibea Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Protibea Therapeutics in its N-PORT filings yet. We sweep new filings monthly.